[go: up one dir, main page]

MX2017008462A - Metodos para utilizar oligonucleotidos antisentido para smad7. - Google Patents

Metodos para utilizar oligonucleotidos antisentido para smad7.

Info

Publication number
MX2017008462A
MX2017008462A MX2017008462A MX2017008462A MX2017008462A MX 2017008462 A MX2017008462 A MX 2017008462A MX 2017008462 A MX2017008462 A MX 2017008462A MX 2017008462 A MX2017008462 A MX 2017008462A MX 2017008462 A MX2017008462 A MX 2017008462A
Authority
MX
Mexico
Prior art keywords
smad7 antisense
methods
patient
antisense oligonucleotides
ibd
Prior art date
Application number
MX2017008462A
Other languages
English (en)
Inventor
andrew smith Scott
Li Xiaobin
ROSSITER Guillermo
L Martin Philippe
R Dewacker Seth
Usiskin Keith
Allan Cline Gary
Original Assignee
Celgene Alpine Invest Company Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Alpine Invest Company Ii Llc filed Critical Celgene Alpine Invest Company Ii Llc
Publication of MX2017008462A publication Critical patent/MX2017008462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen métodos para tratar la enfermedad intestinal inflamatoria (IBD) en un paciente que tiene IBD utilizando oligonucleótidos antisentido para SMAD7.
MX2017008462A 2014-12-26 2015-12-23 Metodos para utilizar oligonucleotidos antisentido para smad7. MX2017008462A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462097012P 2014-12-26 2014-12-26
US201562235269P 2015-09-30 2015-09-30
PCT/US2015/000269 WO2016105516A1 (en) 2014-12-26 2015-12-23 Methods of using smad7 antisense oligonucleotides

Publications (1)

Publication Number Publication Date
MX2017008462A true MX2017008462A (es) 2018-02-26

Family

ID=56151259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008462A MX2017008462A (es) 2014-12-26 2015-12-23 Metodos para utilizar oligonucleotidos antisentido para smad7.

Country Status (17)

Country Link
US (1) US20190112608A1 (es)
EP (1) EP3237018A4 (es)
JP (1) JP2018502107A (es)
KR (1) KR20170105529A (es)
CN (1) CN107405413A (es)
AU (1) AU2015371325A1 (es)
BR (1) BR112017013765A2 (es)
CA (1) CA2971583A1 (es)
CL (1) CL2017001701A1 (es)
CO (1) CO2017007383A2 (es)
EA (1) EA201791471A1 (es)
EC (1) ECSP17040003A (es)
IL (1) IL253023A0 (es)
MA (1) MA41271A (es)
MX (1) MX2017008462A (es)
SG (1) SG11201705179TA (es)
WO (1) WO2016105516A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
US11134889B2 (en) 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
PE20210393A1 (es) * 2018-05-09 2021-03-02 Ionis Pharmaceuticals Inc Compuestos y metodos para la reduccion de la expresion de fxi
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399550A1 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
AU2003231802A1 (en) * 2002-05-17 2003-12-02 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ATE531362T1 (de) * 2006-09-08 2011-11-15 Ore Pharmaceuticals Inc Verfahren zur verminderung oder linderung von entzündungen im verdauungstrakt
EP2476416A1 (en) * 2006-11-17 2012-07-18 Shire Development Inc. Method of Treatment for Inflammatory Bowel Disease
CA2734358A1 (en) * 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
SMT201700346T1 (it) * 2008-11-13 2017-09-07 Nogra Pharma Ltd Composizioni antisenso e metodi per la loro preparazione e loro uso
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CA2848595A1 (en) * 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
MX2016014624A (es) * 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
US20170233736A1 (en) * 2014-10-17 2017-08-17 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
WO2015011694A2 (en) * 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides

Also Published As

Publication number Publication date
EP3237018A4 (en) 2018-07-11
BR112017013765A2 (pt) 2018-02-27
CO2017007383A2 (es) 2018-01-05
WO2016105516A8 (en) 2017-07-06
MA41271A (fr) 2017-10-31
AU2015371325A1 (en) 2017-07-13
IL253023A0 (en) 2017-08-31
CN107405413A (zh) 2017-11-28
EP3237018A1 (en) 2017-11-01
ECSP17040003A (es) 2017-10-31
US20190112608A1 (en) 2019-04-18
WO2016105516A1 (en) 2016-06-30
KR20170105529A (ko) 2017-09-19
SG11201705179TA (en) 2017-07-28
CA2971583A1 (en) 2016-06-30
JP2018502107A (ja) 2018-01-25
EA201791471A1 (ru) 2017-12-29
CL2017001701A1 (es) 2018-04-06

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
EA201790398A1 (ru) Способы лечения заболевания печени
MX2017008462A (es) Metodos para utilizar oligonucleotidos antisentido para smad7.
CL2017002774A1 (es) Secuencias de uricasa mejorada y métodos de tratamiento
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
TW201613639A (en) Methods for treating cardiovascular diseases
GB201022049D0 (en) Methods
MA40574A (fr) Traitement de maladies fibrotiques
RU2014145910A (ru) Способы воздействия на экспрессию гена APOE
RU2014143385A (ru) Способы воздействия на экспрессию гена TP53
RU2014148879A (ru) Способы воздействия на экспрессию гена PRP
RU2014148258A (ru) Способы воздействия на экспрессию гена ADA
RU2014144093A (ru) Способы воздействия на экспрессию гена CRE
RU2014148877A (ru) Способы воздействия на экспрессию гена BRCA1
RU2014142752A (ru) Способы воздействия на экспрессию гена лактазы
RU2014146616A (ru) Способы воздействия на экспрессию гена SNRPN
RU2014144700A (ru) Способы воздействия на экспрессию гена UBE3А
RU2014142755A (ru) Способы воздействия на экспрессию гена CYP17
RU2014142756A (ru) Способы воздействия на экспрессию гена D4DR
RU2014144094A (ru) Способы воздействия на экспрессию гена CREBBP
RU2014142757A (ru) Способ воздействия на экспрессию гена TCF
RU2014145911A (ru) Способы воздействия на экспрессию гена BRCA2